Pharmacokinetics of a New Neuroprotector - Indenoquinoxalinone Derivative after Intravenous Administration in Rabbits and Rats.
Autor: | Yanovskaya EA; E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. elena.yanovskaya@pharmso.ru., Frelikh GA; E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia., Lakeev AP; E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia., Chernysheva GA; E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia., Smol'yakova VI; E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia., Kovrizhina AR; National Research Tomsk Polytechnic University, Tomsk, Russia. |
---|---|
Jazyk: | angličtina |
Zdroj: | Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2023 Oct; Vol. 175 (6), pp. 770-773. Date of Electronic Publication: 2023 Nov 21. |
DOI: | 10.1007/s10517-023-05943-7 |
Abstrakt: | The specific JNK inhibitor and NO donor 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) demonstrated pronounced neuroprotective properties in an in vivo model of ischemic stroke in rats. The pharmacokinetic behavior of IQ-1 was studied in two animal species (rats, rabbits) after intravenous administration in a dose of 1 mg/kg. IQ-1 concentrations in venous blood plasma were measured by the liquid chromatography-tandem mass spectrometry method. The pharmacokinetics of IQ-1 was adequately described by the two-compartmental model. The calculated C (© 2023. Springer Science+Business Media, LLC, part of Springer Nature.) |
Databáze: | MEDLINE |
Externí odkaz: |